Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 2, 2007, Pages 149-153

  Brown, R ^a   Turk, F ^b   Dale, P ^a   Bousquet, J ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Asthma; Cost effectiveness; Economic burden; Omalizumab

Indexed keywords

CORTICOSTEROID; OMALIZUMAB;

ACCURACY; ALLERGIC ASTHMA; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; FATALITY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SEVERE PERSISTENT ASTHMA; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; IMMUNOGLOBULIN E; MARKOV CHAINS; MODELS, ECONOMIC; TREATMENT OUTCOME;

EID: 33846166114     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01310.x     Document Type: Article

References (36)

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
2. Redd SC. Asthma in the United States: burden and current theories. Environ Health Perspect 2002;110(Suppl. 4):557-560.
3. European Respiratory Society and the European Lung Foundation. European lung white book. Brussels, Belgium: European Respiratory Society and the European Lung Foundation, 2003.
4. Seung SJ, Mittmann N. Urgent care cost of uncontrolled asthma in Canada, 2004. Can Respir J 2005;12:435-436.
5. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:61-67.
6. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723-729.
7. Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax 2005;60(Suppl. II):P21.
8. Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, et al. Persistent asthma: disease control, resource utilization and direct costs. Eur Respir J 2002;20:260-267.
9. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006;24:1121-1131.
10. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-248.
11. Sculpher M. The use of quality-adjusted life-years in cost-effectiveness studies. Allergy 2006;61:527-530.
12. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531-536.
13. Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-1776.
14. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-316.
15. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-308.
16. Farahani P, Levine M, Goeree R. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. J Eval Clin Pract 2006;12:463-470.
17. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-708.
18. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-481.
19. Lowhagen O, Ekstrom L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-247.
20. CHKS study. Novartis, data on file.
21. Statistics Canada. Complete life tables, Ontario, 1995-1997. Available at: http://www.statcan.ca/ (Accessed 5 January 2007).
22. Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference-based condition-specific instruments: Converting AQLQ into EQ-5D indices. Sheffield, UK: ScHARR, University of Sheffield, 2002.
23. Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Respir J 2004;13:113.
24. Ontario Drug Benefit Formulary/Comparative Drug Index No. 39, 2005. Available at: http://www.health.gov.on.ca (Accessed 5 January 2007).
25. Canadian Institute for Health Information. Available at: http://www.cihi.ca (Accessed 5 January 2007).
26. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39.
27. Miller MK, Lee JH, Miller DP, Wenzel SE, for the TENOR Study Group. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007, in press.
28. Slavin R, Fox H, Surrey K, Reisner C. Factors predictive of future clinically significant exacerbations in severe asthma. J Allergy Clin Immunol 2006;117:S274.
29. Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 1999;54:301-307.
30. Tough SC, Hessel PA, Ruff M, Green FHY, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-665.
31. Hartert TV, Speroff T, Togias A, Mitchel EF, Snowden MS, Dittus RS, et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89:467-473.
32. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23:287-291.
33. Partridge MR, van der Molen T, Myrseth S-E, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
34. Bateman ED, Boushey HA, Bousquet J, Busse W, Clark TJH, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-844.
35. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006;10:iii-iv;xi-xiv;1-183.
36. Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol Assess 2001;5:1-110.